PHK
NAUT icon

Point72 Hong Kong’s Nautilus Biotechnolgy NAUT Stock Holding History

Point72 Hong Kong’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-906
Closed -$2K – 2241
2022
Q2 		$2K Buy
+906
New +$3.37K ﹤0.01% 1790

Other funds holding NAUT

AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Point72 Hong Kong's NAUT Position: Q3 2022 in Review

Point72 Hong Kong sold out of Nautilus Biotechnolgy (NAUT) in Q3 2022, closing a stake of 906 shares — an estimated $2K sold.

Point72 Hong Kong first reported a position in NAUT in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 86 funds tracked by Wall St. Rank hold NAUT as of Q3 2022.

  • Point72 Hong Kong reported no remaining Nautilus Biotechnolgy position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 906 Nautilus Biotechnolgy shares in Q3 2022, an estimated $2K.
  • Point72 Hong Kong first reported a position in Nautilus Biotechnolgy in Q2 2022 and held it in 1 quarter.
  • Point72 Hong Kong's Nautilus Biotechnolgy position peaked at $2K in Q2 2022.
  • 86 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.